A Phase 3 interventional study of APL-2 and APL-2 in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 112 sites in 14 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 8th largest by enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2018, is one of 15 in phase 3, and was the 53rd registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 637 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 9 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with the worst visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be selected as the study eye.
Ocular- specific inclusion criteria apply to the study eye only, unless otherwise specified.
The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:
Meets the following criteria related to microperimetry:
Female subjects must be:
Exclusion Criteria:
Ocular specific exclusion criteria apply to the study eye only, unless otherwise specified.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
Drug: APL-2
A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
Drug: APL-2
Sham Procedure monthly for 24 months
Other: Sham Procedure
Sham Procedure every other month for 24 months
Other: Sham Procedure
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12
The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 12
LS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 24
The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 24
Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24
The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, 18, and 24 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: From Baseline (screening) through Month 24
LS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24
Mean threshold sensitivity of all points was determined from the mesopic microperimetry as an assessment of the macular functional response. Microperimetry offers the option to test retinal light sensitivity while directly observing the fundus and allows for monitoring of macular function loss associated with GA progression. The microperimetry reading center overlaid the baseline FAF images with GA lesions traced by the imaging reading center and the corresponding macular integrity assessment microperimetry baseline scanning laser ophthalmoscope image and identified perilesional (within 500 microns outside the atrophy border), paralesional (beyond 500 microns outside the atrophy border), and extralesional (outside the atrophy border) loci on the microperimetry grid to determine the mean threshold sensitivity for these 3 areas. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 24
LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24
The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 24
LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24
The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 24
LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24
The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (screening) and Month 24
This Phase III, randomized, double-masked, sham injection-controlled study was conducted in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at 110 sites in 13 countries between 31 Aug 2018 and 28 Jun 2022.
| Milestone | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Monthly | Sham EOM |
|---|---|---|---|---|
| Started | 213 | 212 | 106 | 106 |
| Completed | 144 | 169 | 76 | 82 |
| Not completed | 69 | 43 | 30 | 24 |
| Withdrew: Adverse event | 11 | 8 | 3 | 3 |
| Withdrew: Lost to follow-up | 4 | 5 | 3 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 | 1 |
| Withdrew: Consent withdrawal | 25 | 16 | 12 | 9 |
| Withdrew: Death | 20 | 9 | 7 | 1 |
| Withdrew: Due to coronavirus disease-2019 (covid-19) impact | 9 | 4 | 5 | 8 |
The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| mm^2 | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 | 1.5579 ± 0.08350 | 1.6512 ± 0.08118 | 1.9692 ± 0.08218 |
The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| mm^2 | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 24 | 3.1237 ± 0.14327 | 3.2826 ± 0.13238 | 4.0252 ± 0.14642 |
The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, 18, and 24 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| mm^2 | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| From Baseline to Month 6 | 0.7604 ± 0.04629 | 0.8220 ± 0.04346 | 0.9838 ± 0.04666 |
| From Month 6 to Month 12 | 0.7848 ± 0.05958 | 0.8184 ± 0.05660 | 0.9710 ± 0.05163 |
| From Month 12 to Month 18 | 0.8004 ± 0.05034 | 0.8682 ± 0.04959 | 1.0269 ± 0.05288 |
| From Month 18 to Month 24 | 0.7617 ± 0.6650 | 0.7499 ± 0.04372 | 0.9958 ± 0.05824 |
| From Baseline to Month 24 | 3.1073 ± 0.14841 | 3.2586 ± 0.13420 | 3.9775 ± 0.14310 |
Mean threshold sensitivity of all points was determined from the mesopic microperimetry as an assessment of the macular functional response. Microperimetry offers the option to test retinal light sensitivity while directly observing the fundus and allows for monitoring of macular function loss associated with GA progression. The microperimetry reading center overlaid the baseline FAF images with GA lesions traced by the imaging reading center and the corresponding macular integrity assessment microperimetry baseline scanning laser ophthalmoscope image and identified perilesional (within 500 microns outside the atrophy border), paralesional (beyond 500 microns outside the atrophy border), and extralesional (outside the atrophy border) loci on the microperimetry grid to determine the mean threshold sensitivity for these 3 areas. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| decibels (dB) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Mean Threshold Sensitivity of All Points of the Study Eye at Month 24 | -3.319 ± 0.2969 | -3.064 ± 0.2331 | -2.954 ± 0.2156 |
The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| wpm | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24 | -22.446 ± 3.0329 | -17.533 ± 3.2886 | -16.211 ± 3.8129 |
The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| score on a scale | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24 | -0.287 ± 0.0563 | -0.379 ± 0.0536 | -0.273 ± 0.0554 |
The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| ETDRS letters score | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled |
|---|---|---|---|
| LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24 | -7.477 ± 1.0512 | -8.526 ± 1.0525 | -7.660 ± 1.0734 |
Collected over Treatment-emergent adverse events (TEAEs) were reported from first study drug administration (Day 1) up to the last visit or early termination visit, 30 days after the last study drug administration for the monthly treatment groups and 60 days after the last study drug administration for the EOM treatment groups, a maximum of 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegcetacoplan Monthly: Ocular Study Eye | 0/213 (0%) | 5/213 (2.3%) | 100/213 (46.9%) |
| Pegcetacoplan EOM: Ocular Study Eye | 0/212 (0%) | 4/212 (1.9%) | 95/212 (44.8%) |
| Sham Pooled: Ocular Study Eye | 0/211 (0%) | 1/211 (0.5%) | 59/211 (28%) |
| Pegcetacoplan Monthly: Ocular Fellow Eye | 0/213 (0%) | 1/213 (0.5%) | 69/213 (32.4%) |
| Pegcetacoplan EOM: Ocular Fellow Eye | 0/212 (0%) | 0/212 (0%) | 56/212 (26.4%) |
| Sham Pooled: Ocular Fellow Eye | 0/211 (0%) | 2/211 (0.9%) | 65/211 (30.8%) |
| Pegcetacoplan Monthly: Non-ocular | 20/213 (9.4%) | 77/213 (36.2%) | 86/213 (40.4%) |
| Pegcetacoplan EOM: Non-ocular | 9/212 (4.2%) | 56/212 (26.4%) | 72/212 (34%) |
| Sham Pooled: Non-ocular | 8/211 (3.8%) | 55/211 (26.1%) | 67/211 (31.8%) |
| Event | Pegcetacoplan Monthly: Ocular Study Eye | Pegcetacoplan EOM: Ocular Study Eye | Sham Pooled: Ocular Study Eye | Pegcetacoplan Monthly: Ocular Fellow Eye | Pegcetacoplan EOM: Ocular Fellow Eye | Sham Pooled: Ocular Fellow Eye | Pegcetacoplan Monthly: Non-ocular | Pegcetacoplan EOM: Non-ocular | Sham Pooled: Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 12/213 | 3/212 | 3/211 |
| Atrial fibrillationCardiac disorders | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 7/213 | 1/212 | 6/211 |
| COVID-19Infections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 7/213 | 3/212 | 4/211 |
| COVID-19 pneumoniaInfections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 2/213 | 1/212 | 4/211 |
| Cardiac failure congestiveCardiac disorders | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 3/213 | 3/212 | 3/211 |
| EndophthalmitisInfections and infestations | 2/213 | 3/212 | 0/211 | 0/213 | 0/212 | 2/211 | 0/213 | 0/212 | 0/211 |
| Septic shockInfections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 0/213 | 3/212 | 0/211 |
| Rib fractureInjury, poisoning and procedural complications | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 1/213 | 3/212 | 0/211 |
| Cerebrovascular accidentNervous system disorders | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 3/213 | 1/212 | 2/211 |
| Myocardial infarctionCardiac disorders | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 2/213 | 0/212 | 2/211 |
| Event | Pegcetacoplan Monthly: Ocular Study Eye | Pegcetacoplan EOM: Ocular Study Eye | Sham Pooled: Ocular Study Eye | Pegcetacoplan Monthly: Ocular Fellow Eye | Pegcetacoplan EOM: Ocular Fellow Eye | Sham Pooled: Ocular Fellow Eye | Pegcetacoplan Monthly: Non-ocular | Pegcetacoplan EOM: Non-ocular | Sham Pooled: Non-ocular |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 23/213 | 20/212 | 22/211 |
| Conjunctival haemorrhageEye disorders | 22/213 | 19/212 | 10/211 | 2/213 | 3/212 | 3/211 | 0/213 | 0/212 | 0/211 |
| Visual acuity reducedEye disorders | 17/213 | 20/212 | 17/211 | 13/213 | 11/212 | 19/211 | 0/213 | 0/212 | 0/211 |
| Neovascular age-related macular degenerationEye disorders | 20/213 | 14/212 | 3/211 | 9/213 | 5/212 | 11/211 | 0/213 | 0/212 | 0/211 |
| HypertensionVascular disorders | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 20/213 | 16/212 | 17/211 |
| Vitreous floatersEye disorders | 17/213 | 19/212 | 2/211 | 2/213 | 5/212 | 3/211 | 0/213 | 0/212 | 0/211 |
| Eye painEye disorders | 17/213 | 16/212 | 14/211 | 4/213 | 1/212 | 2/211 | 0/213 | 0/212 | 0/211 |
| FallInjury, poisoning and procedural complications | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 16/213 | 16/212 | 9/211 |
| Punctate keratitisEye disorders | 16/213 | 6/212 | 0/211 | 9/213 | 4/212 | 1/211 | 0/213 | 0/212 | 0/211 |
| COVID-19Infections and infestations | 0/213 | 0/212 | 0/211 | 0/213 | 0/212 | 0/211 | 15/213 | 11/212 | 10/211 |
The intent-to-treat (ITT) analysis set included all subjects assigned to treatment.
| Age, Continuous(years) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Mean | 79.0 ± 7.21 | 78.1 ± 7.81 | 78.6 ± 7.20 | 78.6 ± 7.41 |
| Sex: Female, Male(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Female | 134 | 122 | 136 | 392 |
| Male | 79 | 90 | 76 | 245 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| White | 193 | 196 | 193 | 582 |
| Not Reported | 14 | 12 | 14 | 40 |
| Unknown | 1 | 3 | 3 | 7 |
| Asian | 3 | 1 | 2 | 6 |
| Black or African American | 2 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 7 | 4 | 16 |
| Not Hispanic or Latino | 191 | 193 | 192 | 576 |
| Not Reported | 17 | 12 | 16 | 45 |
| Region of Enrollment(Participants) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| United States | 152 | 148 | 153 | 453 |
| France | 15 | 14 | 15 | 44 |
| Australia | 10 | 14 | 10 | 34 |
| Germany | 7 | 8 | 11 | 26 |
| Czechia | 9 | 7 | 5 | 21 |
| Poland | 6 | 5 | 9 | 20 |
| United Kingdom | 2 | 5 | 4 | 11 |
| Italy | 3 | 3 | 3 | 9 |
| Israel | 3 | 2 | 1 | 6 |
| Netherlands | 3 | 1 | 0 | 4 |
| New Zealand | 1 | 2 | 1 | 4 |
| Spain | 1 | 3 | 0 | 4 |
| Brazil | 1 | 0 | 0 | 1 |
| GA Lesion Size [fundus autofluorescence (FAF)] in the Study Eye(millimeter square (mm^2)) | Pegcetacoplan Monthly | Pegcetacoplan EOM | Sham Pooled | Total |
|---|---|---|---|---|
| Mean | 8.2150 ± 3.91483 | 8.3452 ± 3.95679 | 8.1581 ± 3.69739 | 8.2394 ± 3.85283 |
Showing the first 100 of 112 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Jun 2021, 33 months.
Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jun 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Apellis Pharmaceuticals, Inc. →